Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 2/20 | 0.51 |
| ▸ | PPARG | P37231 | 10/20 | 0.51 |
| ▸ | ACE | P12821 | 4/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.45 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28447871 | 0.83 | MME (0.52) | MMEPPARGACEL3MBTL1FOLH1 | |
| SCHEMBL30200282 | 0.83 | MME (0.52) | MMEPPARGACEL3MBTL1FOLH1 | |
| SCHEMBL3272394 | 0.81 | L3MBTL1 (0.55) | MMEPPARGL3MBTL1 | |
| SCHEMBL7420136 | 0.81 | ALDH1A1 (0.53) | MMEPPARGACENAALAD2 | |
| SCHEMBL7422544 | 0.81 | ALDH1A1 (0.53) | MMEPPARGACENAALAD2 | |
| SCHEMBL27697067 | 0.81 | PPARG (0.56) | MMEPPARGACEL3MBTL1 | |
| SCHEMBL8299830 | 0.81 | PPARG (0.51) | MMEPPARGACEFOLH1NAALAD2 | |
| SCHEMBL5566405 | 0.81 | MME (0.50) | MMEPPARGACEFOLH1NAALAD2 | |
| SCHEMBL7422437 | 0.80 | PPARG (0.48) | MMEPPARGACENAALAD2 | |
| SCHEMBL5819563 | 0.80 | L3MBTL1 (0.54) | MMEL3MBTL1FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9750749-B2 | Methods of treating thyroid eye disease | UNIVERSITY OF ROCHESTER (US) | 2017-09-05 | — | — | US | disclosed |
| US-20160199386-A1 | METHODS OF TREATING THYROID EYE DISEASE | UNIVERSITY OF ROCHESTER (US) | 2016-07-14 | — | — | US | disclosed |
| US-9320723-B2 | Methods of treating thyroid eye disease | UNIVERSITY OF ROCHESTER (US) | 2016-04-26 | — | — | US | disclosed |
| US-20160000777-A1 | METHODS OF USING HISTAMINE RECEPTOR AGONISTS AND ANTAGONISTS | UNIVERSITY OF ROCHESTER (US) | 2016-01-07 | — | — | US | disclosed |
| WO-2014130759-A1 | METHODS OF USING HISTAMINE RECEPTOR AGONISTS AND ANTAGONISTS | UNIVERSITY OF ROCHESTER (US) | 2014-08-28 | — | — | WO | disclosed |
| US-20130045267-A1 | METHODS OF USING AGENTS THAT MODULATE CLAUDIN EXPRESSION | UNIVERSITY OF ROCHESTER (US) | 2013-02-21 | — | — | US | disclosed |
| US-20130046257-A1 | METHODS OF USING AGENTS THAT MODULATE CLAUDIN EXPRESSION | UNIVERSITY OF ROCHESTER (US) | 2013-02-21 | — | — | US | disclosed |
| US-20120015001-A1 | METHODS OF TREATING THYROID EYE DISEASE | UNIVERSITY OF ROCHESTER (US) | 2012-01-19 | — | — | US | disclosed |
| WO-2011097595-A1 | METHODS OF USING AGENTS THAT MODULATE CLAUDIN EXPRESSION | UNIVERSITY OF ROCHESTER (US) | 2011-08-11 | — | — | WO | disclosed |
| WO-2011097596-A2 | METHODS OF USING AGENTS THAT MODULATE CLAUDIN EXPRESSION | UNIVERSITY OF ROCHESTER (US) | 2011-08-11 | — | — | WO | disclosed |
| US-20070135382-A1 | Use of peroxisome proliferator-activated receptor gamma (ppary) and/or retinoic acid receptor (rxr) agonists to inhibit platelet functions | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-06-14 | — | — | US | disclosed |
| EP-1675588-A2 | USE OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA (PPAR GAMMA) AND/OR RETINOIC ACID RECEPTOR (RXR) AGONISTS TO INHIBIT PLATELET FUNCTIONS | University of Rochester (US) | 2006-07-05 | — | — | EP | disclosed |
| WO-2005041872-A2 | USE OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA (PPARϜ) AND/OR RETINOIC ACID RECEPTOR (RXR) AGONISTS TO INHIBIT PLATELET FUNCTIONS | UNIVERSITY OF ROCHESTER (US) | 2005-05-12 | — | — | WO | disclosed |